ECSP23045506A - DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS - Google Patents

DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS

Info

Publication number
ECSP23045506A
ECSP23045506A ECSENADI202345506A ECDI202345506A ECSP23045506A EC SP23045506 A ECSP23045506 A EC SP23045506A EC SENADI202345506 A ECSENADI202345506 A EC SENADI202345506A EC DI202345506 A ECDI202345506 A EC DI202345506A EC SP23045506 A ECSP23045506 A EC SP23045506A
Authority
EC
Ecuador
Prior art keywords
cgas
treatment
conditions associated
derivatives useful
indol derivatives
Prior art date
Application number
ECSENADI202345506A
Other languages
English (en)
Inventor
Oliver Simic
Francesca Perruccio
Carsten Spanka
Florian Gruber
Danilo Guerini
Richard Heng
Martin Gunzenhauser
David Carcache
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP23045506A publication Critical patent/ECSP23045506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente revelación se refiere a un compuesto de Formula (I): (I), o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo farmacéuticamente aceptable, donde R1 hasta R8 son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
ECSENADI202345506A 2020-12-22 2023-06-20 DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS ECSP23045506A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063128949P 2020-12-22 2020-12-22

Publications (1)

Publication Number Publication Date
ECSP23045506A true ECSP23045506A (es) 2023-07-31

Family

ID=79164465

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202345506A ECSP23045506A (es) 2020-12-22 2023-06-20 DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS

Country Status (19)

Country Link
US (1) US20230085472A1 (es)
EP (1) EP4267564A1 (es)
JP (1) JP2024502258A (es)
KR (1) KR20230124665A (es)
CN (1) CN116635382A (es)
AR (1) AR124443A1 (es)
AU (1) AU2021404953A1 (es)
CA (1) CA3202212A1 (es)
CL (1) CL2023001859A1 (es)
CO (1) CO2023007954A2 (es)
CR (1) CR20230282A (es)
DO (1) DOP2023000129A (es)
EC (1) ECSP23045506A (es)
IL (1) IL303913A (es)
MX (1) MX2023007467A (es)
PE (1) PE20240229A1 (es)
TW (1) TW202241873A (es)
UY (1) UY39579A (es)
WO (1) WO2022137085A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391786A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company cGAS INHIBITORS
WO2024083773A1 (en) 2022-10-18 2024-04-25 Glaxosmithkline Intellectual Property Development Limited Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065860A1 (es) * 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
SG11201704770YA (en) 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
BR112020016008A2 (pt) * 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica

Also Published As

Publication number Publication date
WO2022137085A1 (en) 2022-06-30
DOP2023000129A (es) 2023-07-16
PE20240229A1 (es) 2024-02-16
AU2021404953A1 (en) 2023-06-22
IL303913A (en) 2023-08-01
EP4267564A1 (en) 2023-11-01
JP2024502258A (ja) 2024-01-18
UY39579A (es) 2022-07-29
CN116635382A (zh) 2023-08-22
CL2023001859A1 (es) 2024-02-09
AR124443A1 (es) 2023-03-29
CA3202212A1 (en) 2022-06-30
KR20230124665A (ko) 2023-08-25
TW202241873A (zh) 2022-11-01
MX2023007467A (es) 2023-07-04
US20230085472A1 (en) 2023-03-16
CR20230282A (es) 2023-07-12
AU2021404953A9 (en) 2024-02-08
CO2023007954A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
ECSP23045506A (es) DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
CR20160236A (es) Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos
UY38358A (es) Inhibidores de sarcómeros cardíacos
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
UY36257A (es) “compuestos de imidazopiridazina”.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7
CU20140033A7 (es) Derivados de pirrolopirimidina y purina